Strides Pharma Science incurs Rs 162.55 cr. loss in Q2FY22
Strides Pharma Science has reported consolidated financial results for the period ended September 30, 2021
Strides Pharma Science has reported consolidated financial results for the period ended September 30, 2021
The company has operations in North America, Asia, and Europe,
Trivector Biomed has been promoting its Novaerus air disinfection solution across hospitals and health care facilities across India.
Applications remain under review by others including U.S. Food and Drug Administration and the European Medicines Agency
Expertise in exosomes isolation and characterization will drive innovation in this field
Consolidation of the Acros Organics, Alfa Aesar and Maybridge brands to one single brand, Thermo Scientific
New bioinformatic workflow advances analysis capabilities for whole-exome assessment and interpretation
The company is a medical dictation solution used by medical practitioners
Marketing authorisation holders are advised to submit any type IB variations or groupings of type IBs and type IAs by 3rd December 2021 for a start of procedure in 2021
Subscribe To Our Newsletter & Stay Updated